A new meta‑analysis compared CAR‑T cell therapies and bispecific antibodies in relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphomas, synthesizing efficacy and safety across trials. The analysis reported relative response rates, durability metrics and adverse‑event profiles, highlighting where each modality shows strengths and where toxicity or access limit utility. Authors analyzed published trial data to contrast remission durability seen with CAR‑T against the outpatient convenience and repeat dosing of bispecifics, and they quantified rates of cytokine release and neurotoxicity. The work provides clinicians and payers a consolidated evidence base to guide therapy selection and trial design. Biotech companies should use the findings to inform positioning, combination strategies and safety‑management protocols as both platforms compete for similar indications.